Join
Live feed
·
PRReleasevia Quantisnow
Olema Pharmaceuticals Inc. logo

Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

ByQuantisnow·Wall Street's wire, on your screen.
OLMA· Olema Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OLMA (Olema Pharmaceuticals Inc.) and more on Quantisnow.